Glucagon-like peptide-1: difference between revisions
Diff·revision 42 → 43·17:10, 1 Mar 2025
Difference between revision 42 and revision 43 of Glucagon-like peptide-1. 2 lines changed; the page grew by 47 bytes.
| Revision 42 — 23:27, 21 Feb 2025 ArcuateArt (talk) rv promotional edit 10,192 bytes +175 | Revision 43 — 17:10, 1 Mar 2025 HalfLifeHavel (talk) add DOI 10,239 bytes +47 | ||
|---|---|---|---|
| 71 | Actions on the heart, kidney, liver and immune system have all been described, and cardiovascular and renal benefit has been demonstrated for several agonists in outcome trials; the extent to which those benefits are receptor-mediated rather than secondary to weight and glycaemic change remains an open question.{{r|drucker2018}} | 71 | Actions on the heart, kidney, liver and immune system have all been described, and cardiovascular and renal benefit has been demonstrated for several agonists in outcome trials; the extent to which those benefits are receptor-mediated rather than secondary to weight and glycaemic change remains an open question.{{r|drucker2018}} |
| 72 | 72 | ||
| + | 73 | {{seealso|GLP-1 receptor|Beta cell function}} | |
| + | 74 | ||
| 73 | == References == | 75 | == References == |
| 74 | {{reflist}} | 76 | {{reflist}} |